Cryo-Cell International (CCEL)
Cord-blood and cord-tissue banking for families.
Something off on this page? Send us feedback.
Processes and cryogenically stores newborns' cord-blood and cord-tissue stem cells for family use, earning initial service and recurring storage revenue. The business is overwhelmingly family-use banking, supported by U.S. operations, Central American affiliates and long-duration specimen-custody obligations.
Processes and cryogenically stores umbilical-cord blood and cord-tissue stem cells for a newborn's family. Family clients pay for collection kits, testing, processing and initial storage, then annual fees or long-duration plans; international licensees contribute service revenue or royalties. It also sells the PrepaCyte-CB processing system and distributes units from its public cord-blood inventory through NMDP.
Operates U.S. processing, administration and marketing from Oldsmar, Florida, with most specimens stored in Durham, North Carolina, while affiliates serve Central America. AABB and FACT accreditations, cGMP/cGTP-compliant operations, and redundant cryogenic safeguards underpin the custody service, alongside a multi-compartment freezer bag.
Revenue is overwhelmingly tied to family-use banking and its long-term storage commitments. FDA registration and inspection, reliable equipment and data systems, collection-kit and processing suppliers, and NMDP's distribution of public units are continuing operating dependencies.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $3.2M · Total debt $9.0M · Total assets $60.7M · Shareholders' equity −$17.8M
- Revenue
- $7.8M
- Operating income
- $1.2M
- Net income
- $554.6K
Last cut to $0.15 from $0.25 in May 2025.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 21, 2025 | May 21 | May 30 | $0.15 | cut from $0.25 |
| Feb 14, 2025 | Feb 14 | Feb 28 | $0.25 | |
| Nov 15, 2024 | Nov 15 | Nov 29 | $0.25 | |
| Sep 1, 2022 | Sep 2 | Sep 9 | $0.90 | special dividend |
| Institutions12 holders · as of Jun 30, 2026 | 6.89% | 555.1K shares | |
| Insiders1 holder · as of Aug 7, 2026 | 10.51% | 847.6K shares | |
| Strategic holders3 holders · as of Jun 21, 2018 | 23.72% | 1.91M shares | |
| Otherremainder | 58.88% | 4.75M shares |
8.06M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
David PortnoyInsiderdirector, 10 percent owner, officer: Chairman, Co-CEO | 10.51% | 847,629 | Form 4filed Aug 7, 2026 ↗ |
Mary J. Nyberg and Charles D. Nyberg, as co-trustees of CDMJ Nyberg Family Trust, U/A/D June 9, 2005Strategic | 10.50% | 846,780 | 13G/Afiled Feb 14, 2017 ↗ |
Mary J. Nyberg, as trustee of CDMJ Nyberg Family Trust, U/A/D June 9, 2005Strategic | 7.44% | 600,000 | 13G/Afiled Jan 19, 2018 ↗ |
CU Blood, Inc.Strategic | 5.77% | 465,426 | 13Gfiled Jun 21, 2018 ↗ |
Sfi Advisors, LLCInstitution | 2.05% | 165,300 | 13Fas of Jun 30, 2026 |
| See all 18 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- CooperCompanies
CBR is a scaled U.S. family cord-blood and tissue-bank rival.
- Revvity
ViaCord's family cord-blood and tissue bank contests U.S. storage enrollments.
- Azenta
Biorepository scale contests third-party cryogenic-storage demand.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cryo-Cell International | $4.06 | −2.51% | $32.6M | — | 36.9 | 1.0 | −1.6% |
| CooperCompanies | $69.25 | −0.70% | $13.60B | 59.1 | 14.7 | 3.2 | +7.9% |
| Revvity | $129.07 | −1.44% | $14.61B | 62.4 | 23.3 | 5.0 | −1.3% |
| Azenta | $31.75 | +0.57% | $1.46B | — | 55.0 | 2.4 | +12.0% |
| Median | 60.7 | 23.3 | 3.2 | +7.9% |